Nephrotic Syndrome During Ipilimumab Plus Nivolumab Therapy for Sarcomatoid Malignant Pleural Mesothelioma: A Case Report of Nivolumab Rechallenge Without Recurrence of Nephrotic Syndrome. (PubMed, Cureus) - Oct 10, 2026 - "This pattern raises the possibility that ipilimumab alone or the combination of ipilimumab and nivolumab contributed to the development of nephrotic syndrome. This case provides clinical insight into the potential contribution of individual ICIs to ICI-associated nephrotic syndrome and into selective ICI rechallenge as a subsequent treatment strategy."
Journal • Glomerulonephritis • Malignant Pleural Mesothelioma • Mesothelioma • Nephrology • Oncology • Pleural Mesothelioma • Renal Disease • Respiratory Diseases • Sarcoma • Solid Tumor
|
|
Jun Ota; Kazuhiro Shimaya; Makoto Izumi; Shun Endo; Tomoka Yasuda; Yoshikazu Tsukada
|